4-hydroxy-N-(4-methoxyphenyl)-3-quinoline-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-hydroxy-N-(4-methoxyphenyl)-3-quinoline-carboxamide
• 英文别名: 4-hydroxy-N-(4-methoxyphenyl)-3-Quinolinecarboxamide；N-(4-methoxyphenyl)-4-oxo-1H-quinoline-3-carboxamide
• 化学式: C₁₇H₁₄N₂O₃
• 分子量: 294.31
• InChiKey: UFDILRBQIHLZHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甲氧苯胺 、 1,4-二氢-4-氧代-3-喹啉羧酸乙酯 生成 4-hydroxy-N-(4-methoxyphenyl)-3-quinoline-carboxamide
  参考文献：
  名称：

  LE, MARTRET, O.;HUMBERT, D.;HUNT, P. F.

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• INHIBITORS OF MICROBIALLY INDUCED AMYLOID
  申请人：Axial Biotherapeutics, Inc.

  公开号：US20200290970A1

  公开（公告）日：2020-09-17

  The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.

  本公开提供了用于预防淀粉样蛋白形成和治疗与淀粉样蛋白相关疾病的化合物，包括如帕金森病这样的突触核蛋白病。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Sheth Urvi

  公开号：US20120309758A1

  公开（公告）日：2012-12-06

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• 3-Quinoline carboxamides having anxiolytic activity
  申请人：Roussel Uclaf

  公开号：US04450167A1

  公开（公告）日：1984-05-22

  Novel 3-quinoline-carboxamides of the formula ##STR1## wherein R is in 6 or 7-position and is selected from the group consisting of hydrogen, halogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, --CF.sub.3, --SCF.sub.3 and CH.sub.3 S--, R.sub.1 is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, phenyl and benzyl, R.sub.2 is --NHR.sub.4, R.sub.4 is selected from the group consisting of alkyl of 2 to 6 carbon atoms, substituted aryl of 6 to 10 carbon atoms and substituted heterocycle of an aromatic character of 3 to 5 carbon atoms with the proviso that when R.sub.4 is a mono substituted aryl or heterocycle, the substituent is different from R of the quinoline when it is a halogen and R.sub.3 is selected from the group consisting of hydrogen and --OH and their non-toxic, pharmaceutically acceptable acid addition salts having remarkable anxiolytic properties capable of lessening emotional reactions and diminishing states of psychic tension and their preparation.

  3-喹啉羧酰胺的结构式为##STR1##，其中R位于6或7位置，选自氢、卤素、1至6个碳原子的烷基、3至6个碳原子的环烷基、1至6个碳原子的烷氧基、--CF.sub.3、--SCF.sub.3和CH.sub.3S--中的一种；R.sub.1选自氢、1至6个碳原子的烷基、苯基和苄基；R.sub.2为--NHR.sub.4，R.sub.4选自2至6个碳原子的烷基、6至10个碳原子的取代芳基和3至5个碳原子的具有芳香性质的取代杂环，但当R.sub.4为单取代芳基或杂环时，取代基与喹啉的R不同，且当R为卤素时，R.sub.3选自氢和--OH，其非毒性、药用可接受的酸盐具有显著的抗焦虑特性，能减轻情绪反应并减少心理紧张状态，以及其制备方法。